CYPHERPUNK TECHNOLOGIES INC. – Summary of Significant Current Events

Cypherpunk Technologies Inc. has undergone a dramatic transformation, fundamentally shifting its business and strategic direction. This summary details the significant events that shaped this change, typically reported in Form 8-K filings.

---

1. What Happened (Event Description)

Cypherpunk Technologies Inc. fundamentally changed its strategy, shifting its primary focus from biotech. It now operates as a holding company, investing significantly in privacy-enhancing technologies and digital assets, while continuing its biotech operations. Key events include:

• Strategic Rebranding and Pivot (Item 2.01 / Item 5.03): In October 2025, the company, formerly Leap Therapeutics, rebranded as Cypherpunk Technologies Inc. This move signaled a major strategic shift: the company now positions itself as a privacy technology firm, making significant investments in the digital currency Zcash (ZEC). It continues its biotech operations through its subsidiary, Leap Therapeutics.
• Material Investment and Capital Infusion (Item 1.01 / Item 3.02): In October 2025, Winklevoss Capital invested a significant $58.88 million in the company. This investment funded the strategic shift, allowing the company to acquire digital assets and invest in privacy-enhancing technologies.
• Leadership and Advisory Changes (Item 5.02): As the company pivoted, it brought in new leaders and advisors with expertise in the digital asset sector to guide its new direction.
• Restructuring and Workforce Reduction (Item 2.05): To reduce costs and align with its new strategy, the company initiated a restructuring plan, which included layoffs. This plan led to $4.5 million in restructuring charges.

2. When It Happened (Event Date/Timeline)

• Rebranding and Strategic Pivot: October 2025.
• Winklevoss Capital Investment: October 2025.
• Appointment of New Leadership/Advisors: Approximately October 2025.
• Approval of Restructuring Plan and Workforce Reduction: Late 2025 (the company didn't specify an exact date in its initial reports).

3. Who/What is Affected (Impact Assessment)

• Investors: Investors now own a company with a fundamentally different risk profile. Volatile cryptocurrency markets, alongside ongoing biotech ventures, heavily influence its financial performance, which is now significantly tied to the value of its digital asset holdings.
• Employees: Employees experienced layoffs as part of the strategic shift and cost-cutting measures, which impacted morale and operational structure.
• Privacy Tech Community/Zcash Holders: Cypherpunk became a major player in the Zcash ecosystem. It holds 294,743.10 ZEC, valued at $147.4 million as of December 31, 2025, and invests in ecosystem projects like ZODL (a Zcash wallet developer). This brings significant capital and attention to the privacy tech space.
• Biotech Patients/Partners: The company continues to develop sirexatamab, its late-stage clinical asset for DKK1-high colorectal cancer. While this progress remains important, the company's primary financial driver and strategic focus have shifted. Sirexatamab's continued development is now part of a broader, diversified corporate strategy.

4. Financial Impact

The strategic shift and related events had a significant financial impact:

• Capital Infusion: Winklevoss Capital's $58.88 million investment substantially strengthened the company's balance sheet and provided capital for its new strategic direction.
• Asset Holdings: The company now holds 294,743.10 ZEC, valued at $147.4 million as of December 31, 2025. This represents a major portion of its assets.
• Restructuring Charges: The workforce reduction and restructuring plan resulted in $4.5 million in charges.
• Financial Turnaround (as reported in subsequent 10-K): While not an 8-K event, these strategic changes contributed to a reported net income of $4.8 million for fiscal year 2025, a dramatic turnaround from a $67.8 million net loss in 2024. A substantial $50.4 million of this profit came from an "unrealized gain" on Zcash holdings. This means the gain reflects market-driven valuation, not cash generated from operations.
• Cost Reduction: The company significantly reduced costs. This included lower Research & Development (R&D) expenses after completing a major clinical trial, and reduced General & Administrative (G&A) expenses, partly due to the workforce reduction.

5. Key Takeaways for Investors

• New Risk Profile: This is effectively a "new" company. Its financial health now significantly depends on the highly volatile cryptocurrency market, specifically Zcash, in addition to its biotech operations.
• Profit Quality Matters: The reported profit (as seen in subsequent financial statements) is largely non-cash and depends on the market valuation of digital assets. Investors should evaluate performance by focusing on actual cash flow from operations, not just net income.
• Cost-Cutting Impact: Significant cost reductions, including layoffs, demonstrate a lean operational approach and a commitment to efficiency following the strategic shift.
• Dual Business Model Risks: Managing a speculative digital asset portfolio alongside a long-term, high-risk biotech development pipeline creates unique challenges and potential conflicts for capital allocation and strategic focus.
• Regulatory & Market Volatility: Investors should be aware of the inherent regulatory uncertainties in the crypto space and the high market volatility of digital assets. In biotech, clinical trial success and regulatory approval remain significant hurdles.
• Do Your Due Diligence: Review the full 10-K filing (when available) for comprehensive financial statements (balance sheet, cash flow), detailed risk factors, and management's discussion and analysis. This will help you fully understand the company's position and future outlook. Pay close attention to liquidity and how the company plans to fund both ventures.